Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check4 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with a basic error screen and removing navigation to the study details.SummaryDifference19%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous revision label, indicating a newer version of the study page.SummaryDifference0.1%

- Check47 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, representing a minor metadata update to the page version rather than substantive changes to the study details.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision header updated from v3.6.3 to v3.6.4, indicating a minor update to the page version. The study details and visible content are unchanged.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3, indicating a minor deployment/build update for the page. This change does not affect study information or how it is presented to users.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page now displays a newer revision tag (v3.6.2) replacing the previous v3.6.0, indicating a small asset-level update to the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.